Ibrutinib: better combined with other drugs?
Mené sur 40 patients atteints d'une leucémie lymphocytaire chronique récidivante, cet essai de phase II évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité d'un traitement combinant ibrutinib et rituximab
There have recently been an unprecedented number of reports of novel, highly effective drugs for relapsed chronic lymphocytic leukaemia (CLL). These new drugs are the result of a decade of improvements in our understanding of the pathogenesis of CLL, culminating in the development of new targeted treatments. These drugs include first-in-class, orally available compounds like idelalisib (a PI3K
δ inhibitor) and ibrutinib (a BTK inhibitor), both recently registered in the USA for previously treat ...
The Lancet Oncology , commentaire, 2013